Update met systematiek optimale werkhervatting

被引：0
|
作者：
Arianne Lindhout
Jaap van Dijk
Jan Siebers
Chris Kant
机构：
[1] Bohn Stafleu van Loghum,
[2] Bohn Stafleu van Loghum,undefined
来源：
TBV – Tijdschrift voor Bedrijfs- en Verzekeringsgeneeskunde | 2021年 / 29卷 / 9-10期
关键词：
D O I：
10.1007/s12498-021-1430-2
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：46 / 51
页数：5
相关论文
共 27 条
  • [21] Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial
    Hong, D.
    Shergill, A.
    Bazhenova, L.
    Cho, B. C.
    Heist, R.
    Moreno, V.
    Falchook, G. S.
    Nagasaka, M.
    Cassier, P.
    Besse, B.
    Kim, D. W.
    Yoon, S.
    Le, X.
    Zhao, T.
    Atwal, S.
    Park, E.
    Lee, J.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S72 - S72
  • [22] Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial
    Hong, David S.
    Catenacci, Daniel
    Bazhenova, Lyudmila
    Cho, Byoung Chul
    Ponz-Sarvise, Mariano
    Heist, Rebecca
    Moreno, Victor
    Falchook, Gerald
    Zhu, Viola W.
    Swalduz, Aurelie
    Besse, Benjamin
    Kim, Dong-Wan
    Yoon, Shinkyo
    Le, Xiuning
    Zhao, Tingting
    Kadva, Alysha
    Zimmerman, Zachary
    Lee, Jeeyun
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [23] COMBINED PAN-ERBB AND ALK/ROS1/MET INHIBITION WITH DACOMITINIB AND CRIZOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): UPDATE OF A PHASE I TRIAL
    Giaccone, Giuseppe
    Camidge, David Ross
    Jaenne, Pasi A.
    Solomon, Ben
    James, Leonard P.
    Tang, Yiyun
    Martini, Jean-Francois
    Goldberg, Zelanna
    Shreeve, S. Martin
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S297 - S297
  • [24] METxMET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study
    Cho, B. C.
    Ahn, M-J.
    Kim, T. M.
    Kim, S-W.
    Han, J-Y.
    Kim, C.
    Shim, B.
    Ricordel, C.
    Drilon, A. E.
    Pujol, J-L.
    Gray, J. E.
    Villaruz, L.
    Blumenschein, G.
    Perez, J.
    Modi, D. A.
    Kaul, M.
    Patel, S.
    Hao, Y.
    Kim, E.
    Magnan, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S828 - S829
  • [25] A phase I/II study of davutamig (REGN5093), a METxMET bispecific antibody, in patients with MET-altered, advanced non-small cell lung cancer (aNSCLC): Trial in progress update
    Ahn, M-j.
    Cho, B. C.
    Kim, T. M.
    Han, J-y.
    Kim, C.
    Shim, B.
    Drilon, A.
    Blumenschein, G.
    Villaruz, L.
    Gray, J. E.
    Pujol, J-l.
    Lena, H.
    Moro-Sibilot, D.
    Perez, J.
    Modi, D. A.
    Park, J. S.
    Patel, S.
    Li, S.
    Kim, E.
    Magnan, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1673 - S1674
  • [26] Amitriptyline in vergelijking met andere medicamenteuze behandelingen voor depressieGuaiana G, Barbui C, Hotopf M. Amitriptyline versus other types of pharmacotherapy for depression (Cochrane- review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
    Dick Bijl
    Huisarts en Wetenschap, 2004, 47 (1) : 1018 - 1019
  • [27] PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs: approval selpercatinib for solid tumor with RET fusion, gumarontinib for non-small cell lung cancer with MET gene exon 14 skipping mutation, momelotinib for myelofibrosis, bexarotene for adult T-cell leukemia/lymphoma, valemetostat for peripheral T-cell lymphoma, and pirtobrutinib for mantle cell lymphoma in Japan
    Matsumura, Noriomi
    Mandai, Masaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (09) : 1207 - 1208
123